• Connect
  • Bookmark Us
  • AF Twitter
  • AF YouTube
  • AF LinkedIn
  • Subscribe
  • Subscription Link
Arent Fox
  • Firm

    • History

    • Awards & Recognitions

    • Diversity

      • Overview
      • Diversity Scholarship
      • Employees on Diversity
      • LGBT Initiative
      • Women’s Leadership Development Initiative
    • Alumni

    • Pro Bono

      • Overview
      • Current Pro Bono Work
      • Community Involvement
      • Pro Bono Newsletter
      • Pro Bono Awards & Honors
      • FAQ: Pro Bono & Working at Arent Fox
    • Leadership

      • Firm Management
      • Administrative Leadership
  • Deals & Cases

  • People

  • Practices & Industries

    • Practices

      • Advertising, Promotions & Data Security
      • Government Relations
      • Antitrust & Competition Law
      • Health Care
      • Appellate
      • Insurance & Reinsurance
      • Bankruptcy & Financial Restructuring
      • Intellectual Property
      • Commercial Litigation
      • International Trade
      • Communications, Technology & Mobile
      • Labor & Employment
      • Construction
      • Municipal & Project Finance
      • Consumer Product Safety
      • OSHA
      • Corporate & Securities
      • Political Law
      • ERISA
      • Real Estate
      • Environmental
      • Tax
      • FDA Practice (Food & Drug)
      • Wealth Planning & Management
      • Finance
      • White Collar & Investigations
      • Government Contractor Services
    • Industries

      • Automotive
      • Energy Law & Policy
      • Fashion, Luxury Goods & Retail
      • Government Real Estate & Public Buildings
      • Hospitality
      • Life Sciences
      • Long Term Care & Senior Living
      • Media & Entertainment
      • Medical Devices
      • Nonprofit
      • Sports
  • Newsroom

    • Alerts

    • Events

    • Media Mentions

    • Press Releases

    • Social Media

    • Subscribe

  • Careers

    • Lawyers

    • Law Students

    • Professional Staff

  • Contact

    • Washington, DC

    • New York, NY

    • Los Angeles, CA

    Alerts

    • Newsroom Overview
      • Alerts

        Alerts by Criteria

        E.g., 1 / 22 / 2013
        E.g., 1 / 22 / 2013
      • Events
      • Media Mentions
      • Press Releases
      • Social Media
      • Subscribe

    You are here

    Home » Newsroom » Alerts

    Share

    • Printer-friendly version
    • Send by email
    • A Title
    • A Title
    • A Title
    • A
    • A
    • A

    FDA Issues Guidance on Product Recalls

    May 30, 2007

    In November 2003, FDA issued a new Guidance on product recalls. It applies to recalls of all FDA-regulated products: food (including animal feed), infant formula, drugs, medical devices, biologics, and cosmetics. The Guidance essentially consists of a checklist of information the Agency wants industry to provide to FDA in the event of a recall. FDA will use the information to evaluate, classify, monitor, and audit the recall.

    For example, according to the Guidance, companies should submit two complete sets of labeling for the product being recalled, the product’s expected shelf life (if perishable), and the type of packaging used. The recalling company also should explain “in detail” how the recalled product is defective, violative, or both. If, for instance, the recall is due to the presence of a foreign object, the company should describe the object’s size, composition, hardness, and sharpness. The Guidance recommends that a company provide information on how and when the problem occurred, and how and when it was discovered. It further asks that companies submit detailed information about product distribution, such as the number of direct accounts, what type of accounts they are (e.g., repackers, consumers), and geographic areas of distribution.

    According to the Guidance, companies also should submit considerable detail regarding their recall strategy. For example, they should explain their method of notification (letter, phone, email, etc.), identify the parties to whom the notification will be directed, and discuss how they will monitor the effectiveness of the recall. Recalls of products that pose a “significant health hazard” should also be announced in a press release through the Associated Press “to assure the broadest coverage.” FDA will issue a press release itself if it believes such action is warranted (i.e., if the company fails to do so or its release is believed to be inadequate).

    FDA regulations, 21 C.F.R. Part 7, contain general recommendations for recalls, but the Guidance provides more detailed suggestions. Also, the regulations apply only to voluntary recalls, but the Guidance applies to both voluntary and mandatory recalls.

    Related People

    • Brian P. Waldman

    Related Practices

    FDA Practice (Food & Drug)
    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Contact

    Footer Main

    • Firm
    • Deals & Cases
    • People
    • Practices & Industries
    • Newsroom
    • Careers
    • Subscribe
    • Alumni
    • Diversity
    • Legal Notice
    • Privacy Policy
    • Social Media Disclaimer
    • Nondiscrimination
    • Site Map
    • Client/Staff Login

    Offices

    • Washington, DC
      1717 K Street, NW
      Washington, DC 20036
      Tel: 202.857.6000
    • New York, NY
      1675 Broadway
      New York, New York 10019
      Tel: 212.484.3900
    • Los Angeles, CA
      555 West Fifth Street, 48th Floor
      Los Angeles, California 90013
      Tel: 213.629.7400
    • © Copyright 2013 Arent Fox LLP. All Rights Reserved.

      Legal Disclaimer
      Contents may contain attorney advertising under the laws of some states. Prior results do not guarantee a similar outcome.